Recombivax HB

Recombivax HB

 [re-kom´bĭ-vaks″]
a trademark for a preparation of hepatitis B vaccine (recombinant).

Recombivax HB

a trademark for a hepatitis B vaccine (recombinant).

Recombivax HB®

A recombinant hepatitis B vaccine. See Hepatitis B.
References in periodicals archive ?
The two Heplisav doses are administered intramuscularly 1 month apart, compared with the 0-, 1-, and 6-month schedule for the two currently approved hepatitis B vaccines, Engerix-B and Recombivax HB.
The commercial products available are Recombivax HB (Merck, West Point, PA) and Engerix-B (Smith Kline Beecham, Philadelphia, PA).
A study by MSD on its vaccine, Recombivax HB, states that induced protective levels of antibody occur in 96% of 1,213 healthy adults when injected into the deltoid muscle.
Safety in Concomitant Use with RECOMBIVAX HB in Girls and Women 9 Through 26 Years of Age
Results for the first quarter were paced by sales volume gains of established major products, including ZOCOR, MEVACOR, VASOTEC, VASERETIC, PRINIVIL, PEPCID and RECOMBIVAX HB, and by the newer product introductions, CRIXIVAN, COZAAR*, HYZAAR*, FOSAMAX, TRUSOPT and VARIVAX.
In combined trials involving 1216 healthy infants, safety and immenogenicity of Comvax were compared with those of the component vaccines, liquid PedvaxHIB and Recombivax HB, given concurrently.
Results from clinical studies indicate that Liquid PedvaxHIB can be administered concomitantly with DTP, OPV, eIPV (enhanced inactivated poliovirus vaccine), VARIVAX [Varicella Virus Vaccine Live (Oka/Merck)], M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) or RECOMBIVAX HB [Hepatitis B Vaccine (Recombinant)].
5 mcg Haemophilus b PRP; 5 mcg HBsAg) to concurrent administration of monovalent Liquid PedvaxHIB and monovalent RECOMBIVAX HB, anti-PRP levels were measured in 576 of 645 infants who received two doses of COMVAX.
Strategic analysis of all major vaccine brands, such as Pediarix, MMR II, Prevnar, Varivax, Recombivax HB and Fluvirin.
Results for the year were paced by sales volume gains of established major products, including ZOCOR, VASOTEC, VASERETIC, PRINIVIL, PEPCID, RECOMBIVAX HB and M-M-R II, and by the newer product introductions, CRIXIVAN, COZAAR(b), HYZAAR(b), FOSAMAX, TRUSOPT, VARIVAX, VAQTA and COMVAX.
Results for the first nine months were paced by sales volume gains of established major products, including ZOCOR, VASOTEC, VASERETIC, PRINIVIL, PEPCID and RECOMBIVAX HB, and by the newer product introductions, CRIXIVAN, COZAAR(1), HYZAAR(1), FOSAMAX, TRUSOPT and VARIVAX.